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Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2)
gene are a common cause of familial Parkinson’s
disease (PD). Variation around the LRRK2 locus also
contributes to the risk of sporadic PD. The LRRK2
protein contains a central catalytic region, and
pathogenic mutations cluster in the Ras of complex
protein C terminus of Ras of complex protein
(mutations N1437H, R1441G/C and Y1699C) and
kinase (G2019S and I2020T) domains. Much attention
has been focused on the kinase domain, because
kinase-dead versions of mutant LRRK2 are less toxic
than kinase-active versions of the same proteins.
Furthermore, kinase inhibitors may be able to mimic
this effect in mouse models, although the currently
tested inhibitors are not completely specific. In this
review, we discuss the recent progress in the
development of specific LRRK2 kinase inhibitors. We
also discuss non-kinase-based therapeutic strategies
for LRRK2-associated PD as it is possible that different
approaches may be needed for different mutations.
Introduction
Parkinson’s disease (PD) is a relatively common age-
related neurodegenerative disorder [1]. In the past few
years, it has become recognized that there are single-
gene disorders that are clinically and pathologically simi-
lar to sporadic PD [2]. Furthermore, a series of genome-
wide association studies (GWAS) have identified a num-
ber of loci that contribute to the risk for sporadic PD
[3-8].
The most common single genetic cause of autosomal
dominant PD is missense mutations in the leucine-rich
repeat kinase 2 (LRRK2) gene [9,10]. Variation around
the LRRK2 locus also appears to be a risk factor for
sporadic PD [4,11]. Many single-nucleotide substitutions
have been reported in the LRRK2 gene, but only six
have been verified to be pathogenic [12,13]. These
mutations are located predominantly in the enzymatic
domains of LRRK2, including the kinase domain for
which LRRK2 is named. There is a particularly common
mutation, G2019S, in the kinase domain that increases
the kinase activity of the protein (reviewed in [14]).
For many LRRK2 cases, the clinical signs in affected
carriers of the mutation are remarkably similar to idio-
pathic PD and include tremor, rigidity, postural instabil-
ity and bradykinesia [15-17]. There is some variation, as
individual patients may have developed amyotrophy
[18], whereas in one of the first described families, there
is more frequent gait disturbance and less frequent tre-
mor compared to sporadic PD [19]. However, the gen-
eral picture is that LRRK2 causes a disease that overlaps
substantially with sporadic PD.
Because LRRK2 is a kinase, it has been suggested that
targeting kinase activity might be a therapeutic strategy
for familial PD. Furthermore, because LRRK2-related
PD and sporadic PD are clinically similar, it might be
extrapolated that targeting kinase activity might also be
helpful in treating the more common idiopathic form of
the disease.
In this review, we discuss the evidence underlying the
idea that LRRK2’s kinase activity might be modified to
protect against PD. We also focus on the alternative
idea that there are other aspects of LRRK2 function that
might equally be addressed therapeutically. To under-
stand these two ideas, it is important first to identify the
mutations in LRRK2 that are associated with PD and
how these affect protein function.
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LRRK2 has a complex multidomain structure. The cen-
tral part of the protein contains three independent
domains. The Ras of complex protein (ROC) and C ter-
m i n u so fR O C( C O R )b i d o m a i ni sc h a r a c t e r i s t i co ft h e
ROCO family of proteins [20]. The ROC domain binds
GTP, and the COR domain is thought to be a regulator
of ROC GTPase activity [21]. LRRK2 is an active protein
kinase [22,23], although the true physiological target of
this kinase activity has not been resolved.
It has been proposed that the ROC-COR and kinase
domains of LRRK2 may control each other. Mutations
in the ROC domain that prevent GTP binding are
kinase-inactive, leading to the suggestion that the
GTPase activity regulates kinase activity (reviewed in
[14]). Recent evidence presented by two independent
groups, however, showed that kinase activity of LRRK2
is not increased by adding GTP as would be predicted
with the use of this model [20,24]. An alternative inter-
pretation is that the GTP-binding mutants disrupt or
destabilize the ROC domain, resulting in a loss of kinase
activity as a secondary output. It is possible that instead
the kinase domain of LRRK2 regulates the ROC domain
and thus that the kinase domain is the modulator of
activity rather than the output of the protein [12,25].
However, whether this regulation actually happens in
vivo is unknown [14]. Currently, it is thought that there
is some form of regulation between the enzymatic
domains of LRRK2, although the details of the mechan-
isms still need to be resolved.
The flanking ankyrin/heat repeats and leucine-rich
repeat (LRR) domains at the N terminus and WD40
domain at the C terminus are thought to participate in
protein-protein interactions. However, the physiological
role or identification of interactors of these domains and
how these domains dictate LRRK2 function remain
unclear. There may be a role for some of these regions in
the control of LRRK2 kinase activity, as the removal of
sequences from the C terminus has been shown to abol-
ish the phosphorylation ability of LRRK2 [26,27]. Overall,
t h ea v a i l a b l ed a t as u g g e s tt h at LRRK2 is a protein that
has kinase activity, binds GTP and could play a scaffold-
ing role via its protein-protein interaction domains.
Several groups have shown that the G2091S mutation
augments in vitro kinase activity of LRRK2 by two- to
fourfold [22,23,26,28-35]. This might suggest that all
mutants have a simple gain of kinase function mechan-
ism. I2020T is located at the next residue of LRRK2 as
G2019S, but it has either a modest increase [36,37] or a
reduced [26] or no effect [35] on kinase activity levels
compared to wild type (WT). The simplest interpreta-
tion is that the I2020T mutation does not increase
kinase activity, at least in the way it is currently assayed,
which contrasts with G2019S. Therefore, whether all
mutations, even those in the kinase domain, increase
the kinase activity of LRRK2 is uncertain. Some variants
seem to consistently decrease kinase activity, including
the G2385R variant [26] that is a genetic risk factor for
PD in some populations. Therefore, these variants
would seem to be pathogenic by a non-kinase-depen-
dent mechanism.
Another group of LRRK2 mutations is clustered in the
ROC-COR bidomain. The R1441 position in the ROC/
GTPase is mutated to cysteine, glycine or histidine (that
is, R1441C/G/H) in families with PD [10,38-42]. Several
families who have a Y1699C mutation in the adjacent
COR domain have been described [10,43]. A recent
addition to this mutation cluster is N1437H, which was
found in a large Norwegian family with autosomal
dominant parkinsonism [13]. Overall, the balance of the
evidence is that R1441 and Y1699 mutations raise the
kinase activity of LRRK2 only very modestly. In contrast,
the R1441C/G [44-46] and Y1699C mutations consis-
tently lower GTPase activity[ 4 6 ] .T h eG T P a s ea c t i v i t y
for N1437H has not been determined, but it has been
shown that this mutant has increased GTP binding [13],
which is consistent with lower GTPase activity. The
reported GTP-binding capacity of R1441C/G and
Y1699C is less consistent, with some reports of an
increase and others finding no change in GTP binding
[45,47,48]. These effects are probably related, as it has
been proposed that the ROC and COR domains may
interact with each other. R144C destabilizes the ROC
domain [49], whereas Y1699C substitution strengthens
the intramolecular ROC-COR interaction [46]. Although
the precise details still need to be worked out, this sug-
gests that interactions in the ROC-COR bidomain are
important in controlling the GTPase activity of LRRK2
and that this may be dysregulated by mutation.
Although the molecular mechanisms by which muta-
tions affect LRRK2 seem to differ, there are phenotypes
reported at the cellular level that appear to be consistent
between mutations. At least under the conditions of
high-level expression of LRRK2 in vitro,m u t a n tf o r m s
of LRRK2 are acutely toxic [23,27,29,47,50]. For G2019S
LRRK2, there is evidence that cell death also occurs in
vivo with viral vector-mediated expression [51,52].
In cultured neurons, neurite shortening is also a rather
consistent phenotype associated with mutant LRRK2,
even in models where cell death is not apparent
[28,53-58]. Importantly, all mutations tested to date
have one or both of these effects in cells, suggesting that
these are common outputs of the same signaling path-
ways that are affected by mutant LRRK2.
Although not all mutations the have been found to
increase kinase activity of LRRK2 using assays that have
been tried to date, kinase-inactive versions of the same
Rudenko et al. BMC Medicine 2012, 10:20
http://www.biomedcentral.com/1741-7015/10/20
Page 2 of 8mutations are not toxic [23,29,55]. Furthermore, a
kinase-dead G2019S is not toxic to dopaminergic (DA)
neurons in vivo [51]. This implies that pathogenesis is
dependent on having functional kinase activity. This has
led to the idea that the enzyme activity of LRRK2 might
be targeted in developing a new therapeutic drug for
patients with PD.
Therapeutic strategies for LRRK2-associated
Parkinson’s disease
The facts that G2019S, the most frequent mutation in
LRRK2-associated PD, causes augmentation of LRRK2
kinase activity and that cytotoxicity is dependent on
kinase activity lead to the suggestion that inhibition of
LRRK2 kinase activity might be therapeutically benefi-
cial. Given the complexity of the LRRK2 molecule, how-
ever, it is also possible that there are other aspects of
function that might be targeted. Herein we discuss the
possibilities of LRRK2 therapeutic agents from the
standpoint of kinase inhibition, GTP binding inhibition
and other possible alternative avenues for LRRK2-asso-
ciated PD treatment (Figure 1).
Targeting LRRK2 kinase and GTPase activity
One approach to manipulating LRRK2 is to develop
kinase inhibitors, and this is usually accomplished by
making compounds that compete for ATP in the ATP-
binding pocket of LRRK2. The selectivity of most kinase
inhibitors is therefore incomplete, as most will inhibit
other kinases depending on the amount of structural
similarity in this region of the kinase. As might be
expected, several known kinase inhibitors also inhibit
LRRK2, but all have some nonspecific effects [51,59-61].
Because nonspecific inhibition of other kinases can lead
to ambiguous results, the ideal compound with which to
examine LRRK2 function and dysfunctionw o u l dh a v e
maximum selectivity. Two recently reported com-
pounds, LRRK2-IN1 and CZC-25146, have better selec-
tivity than other kinases for LRRK2 [62,63].
These tools are being used in the laboratory to probe
LRRK2 function because they are cell-permeable, but
study of them probably will not proceed to clinical trials
as they do not accumulate in the brain. Experimentally,
one can infuse inhibitors through the cerebral ventricles
[51], but this may not be helpful for humans. Therefore,
one of the key developments needed in the field to test
whether kinase inhibition could work in LRRK2 patients
is to develop specific and potent LRRK2 inhibitors, pre-
ferably ones that can be given orally (discussed in From
bench to bedside: clinical trials and future prospects).
However, there is some data that suggests that chemi-
c a li n h i b i t i o no fL R R K 2m a yn o tg i v et h es a m er e s u l t s
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Figure 1 Schematic representation of potential therapeutic strategies for LRRK2-associated Parkinson’s disease. This diagram highlights
some therapeutic possibilities for leucine-rich repeat kinase 2 (LRRK2)-induced cytotoxicity, taking into account how different mutations cause
different protein biochemical alterations, recruitment of mediators of cytotoxicity or loss of interaction with regulatory proteins such as 14-3-3.
LRRK2 is represented as a simplified linear dimer with the enzymatic ROC-COR-kinase domains, and protein-protein interaction domains, N-
terminal ankyrin, LRR, leucine-rich repeat and WD40. Locations of LRRK2 pathogenic mutations are also shown (N1437H, R1441C/G, Y1699C,
G2019S and I2020T). Broadly, the possible therapeutic points of intervention for LRRK2 are through (A) inhibition of kinase activity and GTP
binding, (B) disruption of LRRK2 dimerization, (C) interference with the protein-protein interaction platform and (D) preservation of constitutive
phosphorylation of LRRK2. Detailed discussion of these approaches can be found in the main text under Therapeutic strategies for LRRK2-
associated Parkinson’s disease.
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Application of kinase inhibitors to cells expressing
LRRK2 causes loss of phosphorylation at S910 and S935,
located at the N terminus of LRR. This is further asso-
ciated with the loss of binding to 14-3-3 protein and
rearrangement of LRRK2 into filamentous structures. In
contrast, kinase-dead LRRK2 retains phosphorylation
and 14-3-3 binding and remains cytoplasmic [35].
Therefore, at least in these cellular assays, kinase-dead
and kinase-inhibited LRRK2 are not the same.
Worryingly, some pathogenic LRRK2 mutants
(R1441C/G, Y1699C and I2020T, but not G2019S) abol-
ished 14-3-3 binding and loss of LRRK2 constitutive
phosphorylation. Additionally, these mutants have more
LRRK2 inclusion bodies formed in the cytoplasm com-
pared to WT LRRK2 bound to 14-3-3 [35]. Therefore,
one must ask if kinase inhibitors might push LRRK2
toward rather than away from a pathogenic form. If this
is true, we cannot yet predict the effects of kinase inhi-
bitors and whether these would be the same as those of
kinase-dead LRRK2. Although there are data supporting
kinase inhibitors preventing neuronal toxicity [51,60],
which might more logically be a predictor of therapeutic
benefit in patients, experiments performed to date have
been done with the less selective agents. Therefore, the
data need to be reassessed with more potent and selec-
tive kinase inhibitors.
It therefore seems appropriate to think about other
approaches for LRRK2 other than kinase inhibition
using competitive ATP inhibitors. Kinases often partici-
pate in ordered signaling cascades, and thus upstream
and downstream effectors of LRRK2 are also attractive
targets for pharmacological therapy for patients with
PD. Modulating the activity of proteins involved in
these cascades could compensate for the impairment of
LRRK2 function caused by mutations. For example, as
shown in LRRK2 Drosophila models, co-overexpression
of 4E-BP on the G2019S-mutant background prevented
neurotoxicity [30]. 4E-BP is a negative regulator
involved in the regulation of translation via binding of
eukaryotic initiation factor 4E (eIF4E). Interestingly,
mutations in EIF4G1 which bind to eIF4E are also asso-
ciated with dominantly inherited parkinsonism [64].
Phosphorylation of 4E-BP by LRRK2 causes release of
eIF4E from being bound to 4E-BP. Because 4E-BP is
also implicated in the mammalian target of rapamycin
pathway, it may be possible to regulate the LRRK2-
induced effects of 4E-BP by using rapamycin. Tain et al.
showed this to be a plausible approach in Drosophila
models, in which they showed that treatment with rapa-
mycin prevented DA neuronal loss [65]. However, the
effect of LRRK2 on 4E-BP has yet to be demonstrated in
LRRK2 mammalian models.
One other possible target is modulation of LRRK2
GTPase activity. Binding of GTP to LRRK2 could
change its conformation, whi c hi nt u r nc o u l dm e d i a t e
interaction with different proteins. GTPases usually
cycle between GDP- and GTP-bound states with differ-
ent affinities for heterologous interactors. For LRRK2,
the data on R1441C and Y1699C having lower GTPase
activity suggest that the GTP-bound form is associated
with disease. Thus blocking the GTP-binding pocket of
ROC or stimulation of GTPase activity to limit a patho-
genic interaction could be a potential therapeutic target
for LRRK2-associated PD [14]. These might be particu-
larly helpful for R1441- and Y1699-mutant LRRK2, but
to date no such tools are available that could achieve
this goal.
Strategies based outside the enzymatic regions
Because LRRK2 has many protein-protein interaction
domains with no catalytic activity, it is possible that
LRRK2 is a scaffold, serving as a platform on which dif-
ferent proteins assemble to perform a specific function.
These domains may play a role in mediating the cyto-
toxicity induced by LRRK2 kinase activity. It has been
s h o w nt h a td e l e t i o no fN - t e r m i n a lL R Rp o r t i o no r
WD40 of G2019S and/or R1441C rescued LRRK2-
induced toxicity in neuronal cells [27,50]. This may be a
point of therapeutic intervention by means of peptide
inhibition in blocking the binding of proteins involved
in mediating LRRK2-induced cytotoxicity as has been
done for other globular proteins that interact [66].
Because the kinase activity of LRRK2 is dependent on
its dimerization, a way to inhibit kinase activity of
LRRK2 selectively could be to disrupt dimeric LRRK2.
This could be achieved by using inhibitory peptides to
interfere with protein folding or dimer formation. This
has been demonstrated to be a successful approach in
HIV studies in which an inhibitory peptide was used to
inhibit the folding of the HIV-1 protease, an important
enzyme in the viral life cycle, thereby inhibiting the life
cycle of the virus and controlling AIDS [67]. This thera-
peutic strategy could be useful for the Y1699C LRRK2
mutant, which has abnormally increased strength of
interaction between the ROC and COR domains.
As discussed in Targeting LRRK2 kinase and
GTPase activity, some mutant forms of LRRK2 lose the
ability to bind 14-3-3 proteins. The mechanisms under-
lying the loss of constitutive phosphorylation and 14-3-3
binding are not known, but it is possible that the func-
tional effect of these changes is to make LRRK2 less
soluble. From this point of view, a possible intervention
is to design a peptide that could serve as a “cap” in pro-
tecting these sites, when unbound to 14-3-3, from being
dephosphorylated by phosphatases. This might more
Rudenko et al. BMC Medicine 2012, 10:20
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LRRK2, which appears not to be toxic in model systems.
From bench to bedside: clinical trials and future
prospects
Given the number of potential ways in which to inter-
fere with LRRK2 dysfunction, it is rather early to discuss
which drugs might be best developed to treat LRRK2-
related PD. There are some obvious issues that may
stand in the way of the assessment and development of
any drug, however, and it is worth discussing those
issues with the goal of identifying key experiments in
the field that should be performed with a long-term
view that LRRK2 is “druggable.”
With the development of any drug, the first step in
assessing the efficacy of the drug is to test it in a suita-
ble animal model. To date, there are more than ten
mouse models carrying different LRRK2-transgenes dri-
ven by different promoters (reviewed in [68]). Disap-
pointingly, these models have not yet fully recapitulated
all the clinical features seen in a PD patient. Although
some DA neuronal death is observed in some of these
models, the loss is not progressive and is rather limited
with mild motor deficits. However, it has been reported
that acute expression of mutant LRRK2 using viral vec-
tors does replicate the DA neuronal cell loss seen in PD
[51,52]. These models might be helpful in that they pro-
vide an opportunity to assess the acute application of
inhibitors and might be the first level of testing novel
agents with transgenic animals used for longer-term
experiments, possibly using phenotypes other than DA
neuronal cell loss if these can be shown to be reliable.
There are some general limitations in the development
of all LRRK2 drugs. First, the potential therapeutic agent
should be able to cross the blood-brain barrier (BBB).
As discussed in Targeting LRRK2 kinase and GTPase
activity, the most promising candidate assessed bio-
chemically and in in vitro models is LRRK2-IN1. When
tested in vivo, however, it was shown that LRRK2-IN1
does not affect the phosphorylation of S910 and S935 of
LRRK2 in the mouse brain, but that it does abolish
phosphorylation of S910/S935 in the kidneys, indicating
that LRRK2-IN1 has poor BBB permeability [62]. These
data suggest that future LRRK2 inhibitors need to have
distinct properties to overcome the current lack of BBB
penetration.
A corollary of this issue is that poor penetration of
LRRK2 therapeutic agents across the BBB could cause
an inadvertent accumulation of the agents in peripheral
tissues. This could raise a potentially important toxicity
problem, as, for example, it was recently shown that
knocking down LRRK2 in mice had deteriorating effects
on kidneys [69,70]. It would therefore be important to
monitor the function of organs in which LRRK2 is
highly expressed, particularly with regard to kidney and
lung function. LRRK2 is also highly expressed in B cells,
so immunological function should be assessed.
Another major problem in the development of LRRK2
drugs is the selectivity of the therapeutic agents. Even
selective LRRK2 medications could have significant off-
target effects if used at high concentrations for an
extended period. For example, it is well-established that
no kinase inhibitor is exclusively selective to a single
kinase [71]. If the concentration of the inhibitor is high
enough, it could inhibit other structurally similar kinases
and cause multiple side effects, a particular problem for
extended use.
Assuming LRRK2 drugs were on hand, one difficult
question would be when it would be most appropriate
to start treatment. One the one hand, it would be logical
to initiate prophylactic treatment in early adulthood in
mutation carriers before the development of classic PD
symptoms. In this case, appropriate therapy could
potentially prevent or delay neuronal degeneration. One
the other hand, mutations in the LRRK2 gene have
incomplete penetrance and variable age at onset. There-
fore, treatment of carriers could lead to long-term treat-
ment of individuals who will not necessarily express the
disease phenotype in their lifetimes, which presents both
ethical and financial hurdles. This might then lead to
the alternative view that any therapy should be
restricted to individuals who have parkinsonism. It is
also relevant that some of the motor aspects of PD are
treatable, if imperfectly, by levodopa and by surgical
approaches such as deep brain stimulation, so a LRRK2-
based strategy would have to have proven benefit com-
pared to current treatments. Efficacy, measurement of
the progression of PD symptoms and the safety of treat-
ments over extended periods will have to be considered
in the development of LRRK2 therapeutic regimens.
Another reasonable question is whether therapeutics
based on LRRK2 could also be beneficial for sporadic
PD. Ultimately, this question cannot be answered with-
out a therapeutic agent in hand, and in all likelihood
this agent would be one that has proven benefit in
LRRK2 cases. If one had an appropriate compound,
however, it would be possible to address the hypothesis
whether LRRK2 PD and sporadic PD are mechanistically
linked, so it is worth thinking about the probability that
this hypothesis would be supported.
On the one hand, LRRK2 is a defined subset of PD
where, as we have discussed, there is even some ques-
tion whether all mutationsw o r ki nt h es a m ew a y .T h i s
would suggest that LRRK2 mechanisms would be rele-
vant only for LRRK2 PD, perhaps even for single muta-
tions. On the other hand, LRRK2 cases are similar
clinically, and sometimes pathologically, to sporadic PD;
therefore, it is possible that the underlying mechanisms
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may play a role in sporadic PD, there is a signal around
the LRRK2 locus in GWAS in sporadic PD that is not
accounted for by specific LRRK2 mutations [4].
Although the genetic basis of this association is unclear,
one interpretation is that changes in the regulation of
WT LRRK2 account for some of the lifetime risk of PD.
By extrapolation, this would support the idea that
LRRK2 is mechanistically linked to sporadic disease and
would predict that LRRK2 therapies should be tried in
idiopathic disease.
Recently, LRRK2 has been associated with an
increased risk in some cancers, in particular melanoma
[72,73]. PD patients with G2019S mutations have a
threefold increased risk of developing melanoma before
the onset of PD [72]. Whether a kinase inhibitor of
LRRK2 would have any impact on cancer is very diffi-
cult to predict, but might be considered a potential
extra target for drug development.
A biomarker of LRRK2 is needed to answer several of
the above questions. Demonstration that a given drug
has the desired effect in humans, that is, shows engage-
ment of the target, will be crucial for deciding whether
a given treatment has actually tested the underlying
hypothesis. Furthermore, having a proximate biomarker
for pathological LRRK2 activity would also be helpful in
deciding whether the protein is involved in sporadic PD.
What such a biomarker would look like is uncertain,
although the action of LRRK2 kinase on a target protein
is an obvious possibility. Development of these types of
markers is eagerly awaited.
Conclusion
We have discussed some therapeutic intervention points
for LRRK2 PD based on what is currently known about
LRRK2 function and LRRK2-induced cytotoxicity.
Although LRRK2 has been implicated in many cellular
pathways, including apoptosis, cytoskeleton dynamics,
protein translation and other cell signaling cascades,
current data are predominantly descriptive and do not
explain much of the underlying molecular mechanisms.
The lack of this knowledge makes the development of
drugs for LRRK2-associated PD difficult. Therefore, elu-
cidation of the exact molecular mechanisms of the neu-
rodegenerative processes caused by different mutations
in LRRK2 would be very valuable in the design of
LRRK2-specific therapeutics. Of all the proven patho-
genic LRRK2 mutations, only G2019S substitution has
augmented phosphorylation activity. Data on other
mutants do not support significant changes in their
kinase function, but they do indicate that other mutants
cause toxicity. This fact allows us to propose that the
therapeutic strategy for PD caused by different LRRK2
mutations could be diversea n dm a yb ed e p e n d e n to n
the unique pathogenic mechanism conferred by each
substitution.
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